Europe Vaccines Market worth $13.74 billion by 2030
The report "Europe Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Forecast to 2030" is projected to reach USD 13.74 billion by 2030 from USD 9.97 billion in 2025, at a CAGR of 6.6% during the forecast period.
Browse 309 market data Tables and 30 Figures spread through 320 Pages and in-depth TOC on "Europe Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-vaccines-market-183602809.html
The Europe vaccines market is experiencing growth, driven by several key factors, including high disease surveillance, an aging population, and adult immunization expansion.
The multivalent vaccines segment is set to register the fastest growth in the Europe vaccines market by type.
Based on the type, the market is divided into multivalent vaccines and monovalent vaccines. During the forecast period, the multivalent vaccine was the fastest-growing segment. This is mainly due to the need for next-generation multivalent vaccines to provide a more protective spectrum against multiple causative pathogens in a single vaccine dose, such as hexavalent pediatric combinations, due to public health needs for greater immunological efficacy and compliance.
Conjugate vaccines are estimated to account for the highest share in the Europe vaccines market by end user during the forecast period of 2025 to 2030.
By technology, the market is divided Conjugate vaccines, recombinant vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines., conjugate vaccines command the highest market share in 2024, this arises from their superior immunogenicity against encapsulated bacteria, widespread inclusion in national pediatric schedules for pneumococcal, meningococcal, and Hib protection, and proven long-term efficacy in reducing invasive disease burdens.
Germany accounted for the largest regional share in the Europe vaccines market (excluding COVID-19) in 2024.
The market for North America proteomics is segmented into Germany, the UK, France, Italy, Spain, and the rest of Europe. Germany held the highest share in 2024, primarily due to its advanced immunization infrastructure, high vaccination rates across pediatric and adult populations, substantial investments in research and development, and robust government backing for routine immunization programs. Germany is expected to maintain leadership moving forward.
Key players in the Europe vaccines market include GSK Plc. (UK), Sanofi (France), Bavarian Nordic (Denmark), AstraZeneca Plc (UK), CSL (Australia), Pfizer (US), Merck & Co., Inc. (US), and Johnson & Johnson Services, Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
